Navigation Links
Merck Serono Announces Initiation of the ORACLE MS Trial to Evaluate Cladribine Tablets in Patients at Risk of Developing Multiple Sclerosis
Date:9/17/2008

ne tablets in delaying the development of definite MS.

In the study, Cladribine tablets are given in two or four treatment cycles in the first year, with each cycle consisting of once daily administration for four to five consecutive days, which means study patients take Cladribine tablets for only 8 to 20 days during that year. In the second year, two treatment cycles are administered to all patient groups.

The primary endpoint of the ORACLE MS trial is time to conversion to MS, according to the McDonald criteria. Other endpoints include time to conversion to clinically definite MS according to the Poser criteria (the main secondary endpoint), assessments of MRI brain scans, and disability progression.

Approximately 200 medical centers globally are expected to participate in this trial.

(1) CLARITY: Cladribine Tablets Treating MS Orally

About Cladribine tablets

Merck Serono's proprietary oral formulation of Cladribine is currently being evaluated in Phase III as a treatment for patients with relapsing forms of multiple sclerosis (MS). Cladribine is a small molecule that may interfere with the behavior and the proliferation of certain white blood cells, particularly lymphocytes, which are thought to be involved in the pathological process of MS.

About Rebif(R)

Rebif(R) (interferon beta-1a) is a disease-modifying drug used to treat relapsing forms of multiple sclerosis (MS) and is similar to the interferon beta protein produced by the human body. The efficacy of Rebif(R) in chronic progressive MS has not been established. Interferons are thought to help modulate the body's immune system and reduce inflammation. The exact mechanism is unknown.

Rebif(R), which was approved in Europe in 1998 and in the US in 2002, is registered in more than 80 countries worldwide. Rebif(R) has been proven to delay the progression of disability, reduce the frequency of relapses and reduce MRI lesion activity and area*. Rebif(
'/>"/>

SOURCE Merck Serono International S A
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Merck/Gilead Once-A-Day AIDS Pill Not Available in Most Places - AHF Urges Speed-Up of Registrations
2. GeoVax Labs, Inc. Comments on Discontinuance of Mercks HIV Vaccine Trial
3. MJFF and Merck Serono (EMD Serono in North America) Join Forces on $2-Million Initiative to Drive Treatments for PD-Related Cognitive Dysfunction and Mood Disorders
4. Ambrx Enters FGF-21 Type 2 Diabetes Drug Discovery Collaboration with Merck and Co. Inc.
5. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
6. Microbicide Developer Receives License for Novel HIV Microbicide Candidate From Merck & Co., Inc.
7. Iomai and Merck & Co., Inc. Evaluate Use of Iomai Immunostimulant Patch
8. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
9. MicroDose Technologies Announces Achievement of Phase I Clinical Milestone Triggering First Milestone Payment Under Collaboration with Merck & Co., Inc.
10. Diakron Licenses Anticoagulant Drug Candidate from Merck & Co., Inc.
11. Merck Serono Completes Enrollment in the REFLEX Trial of Rebif(R) in Patients at Risk of Developing Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... from institutional investors to purchase an aggregate of approximately ... at-the-market registered direct offering, led by a dedicated health ... purchase agreements with these investors pursuant to which the ...
(Date:1/15/2014)... Jan. 15, 2014  Humberto C. Antunes,  Galderma  worldwide CEO, ... the Journal of Drugs in Dermatology (JDD) ... (ODAC). The event is January 17-20, 2014, at the Omni Orlando ... The ODAC is a distinguished event ...
(Date:1/15/2014)... PALM BEACH GARDENS, Fla. , Jan. 15, 2014  In an ... C. difficile and TB in ambulances and other transport vehicles, an ... being used by rescue personnel for the first time. ... coming in contact with these deadly pathogens, West Palm ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Superbugs No Longer Ride In Rescue Vehicles 2
... PRINCETON, N.J., Jan. 4, 2011 Pharmasset, Inc. (Nasdaq: ... 29th Annual J.P. Morgan Healthcare Conference to be held January ... CA. Schaefer Price, President and Chief Executive Officer, will provide ... at 9:00 AM (PT). To access a simultaneous ...
... Jan. 4, 2011 Boston Scientific Corporation (NYSE: ... M.D., Chief Medical Officer, Cardiac Rhythm Management, on an article ... the American Medical Association .  The article reported on a ... received an implantable cardioverter defibrillator (ICD) did not meet evidence-based ...
Cached Medicine Technology:Pharmasset to Present at the 29th Annual J.P. Morgan Healthcare Conference 2Pharmasset to Present at the 29th Annual J.P. Morgan Healthcare Conference 3Statement of Kenneth Stein, M.D., Chief Medical Officer, Cardiac Rhythm Management, Boston Scientific on JAMA Article 2
(Date:4/23/2014)... Oncotarget , explored tumour heterogeneity where ... DNA signatures within the same cancer. Such differences ... treatment strategies. , Firstly they confirmed the mutual ... KRAS or BRAF mutation. Secondly, they found that ... have that specific mutation present uniformly throughout the ...
(Date:4/23/2014)... endogenous neural precursor cells cannot alone compensate for ... perspective of neural plasticity, Dr. Yun Xiang and ... the effects of functional electrical stimulation treatment on ... basic fibroblast growth factor and epidermal growth factor ... The researchers found that functional electrical stimulation can ...
(Date:4/22/2014)... the United States with 1 million participants annually. A ... Injury Research and Policy at Nationwide Children,s Hospital is ... distribution patterns of basketball-related injuries treated in emergency departments ... and teens. , The study, published online in the ... to adolescents 13-19 years of age who were treated ...
(Date:4/22/2014)... FDA-approved device has been shown to reduce seizures in ... percent. When coupled with an innovative electrode placement planning ... the complete elimination of seizures in nearly half of ... trials. , That,s good news for a large portion ... with epilepsy whose seizures can,t be controlled with medications ...
(Date:4/22/2014)... Health clinics that can provide primary care for ... both hospitals and insurance companies while improving patient ... hospital admissions suggests that health clinics that avoid ... save money by lowering hospital admission rates and ... of economics, Penn State Altoona. , The ...
Breaking Medicine News(10 mins):Health News:Non-uniform genetic mutations identified in lung cancers could lead to targeted treatment 2Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 2Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 3Health News:Newly approved brain stimulator offers hope for individuals with uncontrolled epilepsy 2Health News:Clinics not bogged down by red tape can ease health cost burdens 2
... Researchers have discovered two common genetical variants that increase ... kidney disease is a condition in which kidneys of ... the correct fluid and waste balance that is part ... wastes in the body that can lead to toxicity ...
... have therapeutic properties that can be effective// against mental ... of the Universitat Autònoma de Barcelona in Spain have ... isolating a harmless part of the toxin called the ... from being transported by the synaptic membranes, and thus ...
... can ward off an attack of premenstrual syndrome// (PMS). ... symptoms that affect a lot of women a week ... of PMS are depression, feelings of aggression and mood ... social interactions and relationships are getting affected because of ...
... the graft to bypass a blockage in the blood// vessels ... graft to bypass blockages, scientists often use plastic prosthetic tubes. ... have dialysis. This is called a shunt. The problem with ... vessels, the blood flows twisting and turning as the artery ...
... weight may help themselves from the incidence of diabetes ... ,Diabetes affects the population in terms of affecting the ... insulin that helps in controlling the blood sugar levels. ... inactivity, genetic influence and age related factors. Recent studies ...
... has suggested that obesity,in middle age increases the ... a progressive,brain dysfunction that occurs most commonly late ... daily activities. ,The 27 year longitudinal study ... analyzed,prospective data from a population of around 10276,males ...
Cached Medicine News:
Automatic tangent screen with plane type central field tester. Static, quantitative perimetry....
... represents the latest breakthrough in visual ... the Humphrey Matrix will help you ... and assess treatment alternatives. Enhanced patient ... complete long-term glaucoma care for your ...
Preference Toric quarterly planned replacement lenses are durable, easy to handle and virtually maintenance free. Meeting the needs of those suffering from astigmatism, these soft contact lenses are ...
... and disposable lens convenience for those with ... want crisp, clear vision with the convenience ... Vertex Toric lenses are manufactured using our ... a perfect edge on every lens. This ...
Medicine Products: